| Lauren Jones, CFY-SLP | |
|
1871 Nw Gilman Blvd, Suite 2, Issaquah, WA 98027-8116 | |
| (425) 657-0620 | |
| Not Available |
| Full Name | Lauren Jones |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1871 Nw Gilman Blvd, Issaquah, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073942942 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SI60403744 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Jones, CFY-SLP 1871 Nw Gilman Blvd, Suite 2, Issaquah, WA 98027-8116 Ph: (425) 657-0620 | Lauren Jones, CFY-SLP 1871 Nw Gilman Blvd, Suite 2, Issaquah, WA 98027-8116 Ph: (425) 657-0620 |
News Archive
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced results from the Phase 1/2 clinical trial of OMS201, the Company's urological PharmacoSurgery™ product candidate.
A research study led by scientists from the Gregorio Marañón University Hospital in Madrid and the Network of Centres for Biomedical Research in Mental Health Networks (CIBERSAM) shows that adolescents experiencing a first outbreak of psychosis have lower levels of grey matter in their brains than healthy teenagers. Strangely, this change was seen in patients suffering from various psychoses, including bipolar illness and schizophrenia.
The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.
Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.
"Focused ultrasound has the potential to be a game-changing technology that could impact the lives of millions of people with serious medical disorders including essential tremor," says Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation and former Co-Chair of Neurosurgery at the University of Virginia.
› Verified 6 days ago
Mrs. Nancy M Lestz, MA,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 710 Nw Juniper St, Suite 110, Issaquah, WA 98027 Phone: 425-392-2631 Fax: 425-392-4631 | |
Lynn Bonko, SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 710 Nw Juniper St, Suite 110, Issaquah, WA 98027 Phone: 206-805-9108 | |
Jennifer Benoliel, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 710 Nw Juniper St, Issaquah, WA 98027 Phone: 425-392-4965 | |
Mark Russel, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 319 Nw Dogwood St, Issaquah, WA 98027 Phone: 425-373-1315 | |
Rebecca Kneepkens, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5150 220th Ave Se, Issaquah, WA 98029 Phone: 425-837-6500 | |
Danielle Justine Hulse, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1495 Nw Gilman Blvd Ste 4, Issaquah, WA 98027 Phone: 425-392-2346 |